Baidu
map

Nat Genet:全球科学家通力合作在结核病研究上取得重大突破!

2016-11-15 佚名 生物谷

图片摘自:imgarcade.com 肺结核是威胁全球公众健康的一种疾病,对患者治疗通常需要数月,而且截止到目前为止,针对肺结核并没有有效的疫苗来进行预防;多种不同的结核分枝杆菌在全球很多地方都存在,而且其具有不同的地理分布,仅有所谓的菌株谱系4是在各大洲都存在的,在每年新发的1000万感染者和死亡的200万患者中,大部分个体都是因这类菌株而感染。 近日,一项刊登在国际杂志Nature G

图片摘自:imgarcade.com

肺结核是威胁全球公众健康的一种疾病,对患者治疗通常需要数月,而且截止到目前为止,针对肺结核并没有有效的疫苗来进行预防;多种不同的结核分枝杆菌在全球很多地方都存在,而且其具有不同的地理分布,仅有所谓的菌株谱系4是在各大洲都存在的,在每年新发的1000万感染者和死亡的200万患者中,大部分个体都是因这类菌株而感染。

近日,一项刊登在国际杂志Nature Genetics上的研究报告中,来自全球56家研究机构的75名科学家通过联合研究对来自数千名结核病患者机体中结核分枝杆菌的遗传组成进行了深入分析,研究者发现,结核分枝杆菌谱系4型在遗传学上能够被分为多个子谱系,某些子谱系菌株在全球均有分布,而其它菌株则主要受限于地理学分布。

研究者指出,结核分枝杆菌往往会被分为全球分布的通用型菌株和重点关注局部生态环境的特殊菌株;结核分枝杆菌有着独特的特性,其几乎不会改变它们自身的抗原,而且细菌也能够被机体免疫系统有效识别,一旦机体强烈的免疫反应发生就会影响肺部的健康,进而促进感染者咳嗽,同时结核分枝杆菌还能够在人群之间有效地传播。

普通的从业医生经常会寻找别的方法来治疗细菌感染,而这通常会增加细菌抗原的多样性,研究者Stefan Niemann指出,通用型菌株往往会寻找到额外的方法,相比特殊菌株而言其能够增加细菌表面抗原的多样性,同时通用型的菌株还会对不同人群的机体免疫系统产生特殊的免疫反应,而且这类细菌通常会采用特殊的分子策略来在全球实施扩散。

这项研究发现对于开发新型结核分枝杆菌的疫苗具有重要意义,细菌适应的抗原越多,研究者们就越难设计出特殊疫苗来有效应对细菌的感染,因此研究者们就需要通过未来深入的研究来开发具有广谱性的活性结合分支杆菌的疫苗。这项研究中,研究者们通过全球通力合作深入剖析了多名感染者机体中结核分枝杆菌的遗传组成,对于后期开发新型结合疫苗提供了新的线索,同时也为抵御其它诸如HIV等全球感染性疾病的发生提供了一定的研究依据和帮助。

原始出处

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733805, encodeId=1e221e33805b6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 27 18:08:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048743, encodeId=6f472048e4387, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 15 01:08:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686042, encodeId=70aa1686042c4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Oct 28 07:08:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254013, encodeId=2a29125401397, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 17 01:08:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881441, encodeId=796e188144100, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 07 04:08:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-10-27 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733805, encodeId=1e221e33805b6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 27 18:08:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048743, encodeId=6f472048e4387, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 15 01:08:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686042, encodeId=70aa1686042c4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Oct 28 07:08:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254013, encodeId=2a29125401397, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 17 01:08:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881441, encodeId=796e188144100, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 07 04:08:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-10-15 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733805, encodeId=1e221e33805b6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 27 18:08:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048743, encodeId=6f472048e4387, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 15 01:08:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686042, encodeId=70aa1686042c4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Oct 28 07:08:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254013, encodeId=2a29125401397, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 17 01:08:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881441, encodeId=796e188144100, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 07 04:08:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733805, encodeId=1e221e33805b6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 27 18:08:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048743, encodeId=6f472048e4387, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 15 01:08:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686042, encodeId=70aa1686042c4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Oct 28 07:08:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254013, encodeId=2a29125401397, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 17 01:08:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881441, encodeId=796e188144100, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 07 04:08:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1733805, encodeId=1e221e33805b6, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 27 18:08:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048743, encodeId=6f472048e4387, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 15 01:08:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686042, encodeId=70aa1686042c4, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Oct 28 07:08:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254013, encodeId=2a29125401397, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Nov 17 01:08:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881441, encodeId=796e188144100, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 07 04:08:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-09-07 liye789132251

相关资讯

Respirology:姜黄素可能用于治疗结核病

纯天然的姜黄植物具有消炎和抗氧化的特性,因此,它具有强大的药效,可以预防和治疗多种疾病。 姜黄的活性成分为姜黄素,有治疗功效。现在一项新研究指出,姜黄素具有消除耐药的结核杆菌(TB)的作用。抗结核药物的耐药性是一个重大的公共卫生问题,威胁到全球结核病患者的治疗效果和疾病控制进程。 在研究中,研究人员发现,姜黄素可刺激人类巨噬细胞并清除被结核分枝杆菌感染的细胞。研究人员指出,过程中的激活分子称为NF

Lancet:入境前进行结核病筛查的结果分析

结核病低发生率国家欲消除结核病,需要通过多种干预措施,包括移民筛查。我们对进入英格兰、威尔士和北爱尔兰的人群进行了结核病的移民筛查,并在他们进入这些区域后,跟踪结核病的发生发展情况。 移民筛查的国际组织对所有≥11岁、打算停留超过6个月、申请英国签证的参与者进行了筛查。申请人接受胸片检查,以及其他结核病检查,包括痰培养等。对测试结果阴性、进入到英格兰、威尔士和北爱尔兰的申请人,我们进行了跟踪

2016NICE指南——结核病(NG.33)发布

2016年1月,英国国家卫生与临床优化研究所 (NICE)发布了结核病指南,以替代第177号指南。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Respirology :姜黄素有助于治疗耐药结核病

    由结核分枝杆菌引起的结核病仍然是世界范围内主要的传染病杀手。根据WHO最新报道2014年全世界有960万人患结核病,150万人死于该疾病。2014年,全球预计48万人患耐多药结核病。结核病还是艾滋病毒阳性患者的首要死因,2015年,三分之一的艾滋病死亡是由结核病引起的。中国是结核病发病人数较高的国家,仅次于印度。联合起来消除结核病,这是2

Medicine:长期应用ACEI与结核病风险下降相关

大量的流行病学资料表明,使用血管紧张素转换酶抑制剂(ACEI)可改善肺炎的临床预后。结核病(TB)是一种空气中的细菌导致的肺部疾病,像是肺炎。研究者旨在探讨应用ACEI是否能够降低活动性肺结核的风险。研究者应用来自台湾全民健康保险研究资料库中的100万纵向随访队列,进行了一项巢式病例对照研究。应用条件Logistic回归估计TB的RR值,并采用涉及71个结核病相关协变量的结核病特定疾病风险评分(D

耐药结核病治疗方案

结核病是一个古老的疾病,几千年来由于没有有效的抗结核治疗药物,在上个世纪40年代以前是人类死亡的主要疾病。自从1943年链霉素发现以来, 结核病治疗进入了化疗时代,到上个世纪60年代,共有十余种抗结核药物问世,结核病疫情得到有效控制。但随着抗结核药物应用时间的延长,耐药问题逐渐成为结核病控制的主要问题,使全球结核病疫情变得十分严峻。我国每年有12万耐药结核病患者,患者人数居世界第二位。抗结核药物分

Baidu
map
Baidu
map
Baidu
map